Adamis Pharma announced license to commercialize Tempol, a novel investigational anti-inflammatory and antioxidant drug for treatment of respiratory diseases
On Jun. 15, 2020, Adamis Pharma announced a license to commercialize Tempol, a novel patented investigational drug for the treatment of Coronavirus (COVID-19). The license includes the worldwide use of Tempol for the treatment of all respiratory diseases including asthma, respiratory syncytial virus, influenza and COVID-19. The license was obtained from Matrix Biomed.
Tags:
Source: Adamis Pharmaceuticals
Credit:
